While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Pfizer said the new forecast includes a one-time charge of 20 cents per share related to its recent licensing deal with China ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...

The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.